The interaction between an antibody and its epitope has been daily utilized in various biological studies; however it has been rarely explored whether small molecules can alter the interaction. We discovered that small molecules could alter/edit surface properties of amyloid beta (Aβ) epitopes, and consequently inhibit or enhance corresponding antibody recognition. Remarkably, this editing effect could generate functional changes including protein aggregation behaviors, cell cytokine secreting and in vivo microglia activation. According to this discovery, we proposed a screen 2 platform based on epitope editing for drug discovery (SPEED). With a small library of compounds, we validated that SPEED could be used to seek new leads for Aβ species.
Introduction
Genes and proteins are the most essential components linked with functions of a living organism. While genes encode information, proteins execute biological functions.
Genome editing, which enables adding, removing, or altering nucleotide sequences at specified positions, is currently considered as one of the most powerful tools for fundamental biological studies and clinical research. 1, 2 In parallel with genome editing, the alteration of amino acid sequence and hierarchical structures could be considered as editing action of a protein. Numerous approaches to modify/edit the amino acid sequence have been reported and explored for studying basic mechanism and for seeking therapeutics. 3, 4 For the hierarchical structures of a protein, surface properties including charge/electrostatic force and hydrophobicity/Van der Waals forces are the primary determinants. Alternation of charge and hydrophobicity of an amino acid sequence of interest could also be deemed an editing process. For an antigen of a protein/peptide, an epitope is normally the antibody binding sequence of amino acids, and it can be the whole sequence or a fragment. 5 Although the epitope-antibody 3 interactions have been extensively applied in various biological studies, it has been rarely explored whether the interaction can be altered by inserting an additional molecule. For the binding between an antigen with its antibody, charges and hydrophobicity are the major interacting forces. 6 We speculated that, when a molecule (editor) bind to an epitope, the readout of corresponding antibody binding could be different due to the altering/editing of the surface properties. We posited that this phenomenon could be used as a screening strategy to determine whether the molecule (editor) can bind to the epitope (protein) and reflecting the degree of epitope-drug interactions. We termed it "screening platform based on epitope editing for drug discovery (SPEED)". To the best of our knowledge, such investigation has been so far neglected.
In the present study, we demonstrated that SPEED could be used to establish a versatile screening platform to seek and validate ligands, therapeutics, and imaging probes. Amyloid beta (Aβ), one of the major hypothesized pathogenic targets in Alzheimer's disease (AD), was first selected as the model protein for proof-of-concept studies, in which we investigated the altering/editing effect of charge and hydrophobicity of Aβ fragment on antibody binding. Next, we investigated functional changes after altering/editing Aβ epitope, include protein aggregation behaviors, cytokine secretion from microglial cells and in vivo microglial activation. With very encouraging results, we explored whether SPEED could be used to screen for Aβ leads with a small library of 32 compounds. Lastly, we used tau protein and PD-L1 protein as two additional examples to further demonstrate the potential applicability of SPEED.
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The SPEED strategy requires no modification or tagging of the tested protein and the drug candidate, and can be easily and widely implanted into many biomedical laboratories without extra equipment. We believe that SPEED is an important complement for the currently available drug screening approaches.
Results
Experimental design for proof-of-concept. Over the past decade, our research group has been working on imaging probe development for Aβ species. In the course of our studies, we observed that some molecules could potentially alter the surface properties of certain fragments of Aβ peptides. Based on the observations, Aβ was selected as the model protein for proof-of-concept studies. Additional considerations include: 1) Aβ is one of the primary hypothesized pathogenic targets in AD and was reported to correlate with neuroinflammation and production of auto-antibodies. 7 Clearly Aβs could be considered as an antigen and its fragment as an epitope; 2) Surface properties of Aβ play a major role in protein assembly and are closely associated with its toxicity, enzyme activation, oxidative stress and other functions; 8,9 and 3) Aβ already has commercially available antibodies for various known epitopes. 10 Next, we set out to choose a proper method for target protein immobilization.
Rather than using resins, capture antibodies, and functional groups to trap/react with target proteins, we used dot blot immunoassay as the screening platform for straightforward investigation due to: 1) no extra modification of protein is required, which could maintain the original structure properties of proteins; 2) the changes of target epitope can be easily monitored by amplified fluorescence and 5 chemiluminescence signals from antibodies (the most widely used technique for readout of Western blot and ELISA); 3) the methodology validations of dot blot have already been well-established, showing high sensitivity with detecting limit as low as picogram quantities. With rapid and easy procedures, dot blot enables dozens of assays on one assay strip; 4) the inexpensive apparatus enable fast immobilization of proteins that could be easily and widely implanted into many biomedical laboratories. 11, 12 In our studies, the screening platform was successfully set up via the following procedure:
protein/peptidic antigen with or without drug/editor treatment was immobilized on a nitrocellulous membrane using Bio-Dot Microfiltration Apparatus. Each strip including 5-6 duplications was assigned to corresponding antibody recognition for epitope of interest (EOI). The chemiluminescence readout from control group (without tested drug/editor) was normalized to 1.0, and the editing effect for EOI was quantified using the ratio between the two groups.
Charge/Electrostatic Editing of Aβs. Charge/electrostatic interactions on an epitope play critical roles for antibody recognition by cation-π interaction, anion-π interactions and hydrogen bond formation. 6 To investigate whether modulating electrostatic interactions on an epitope could lead to changes of antibody-binding readout, we choose 12-crown-4 ether as a model compound for charge/electrostatic editing. Previously we found that 12-crown-4 could attenuate the aggregation of Aβs. 13 Reportedly, crown ethers could form hydrogen bonds with positively charged amino groups (e.g. lysine,
arginine, histidine) to shield the charge, 14 and the sequence of Aβ peptides contains important lysine (K16), a crucial amino acid that forms inter-sheet salt bridges and 6 promotes mis-folding of Aβ. 9 Thus, we hypothesized that 12-crown-4 could interact with the positively charged e-amino of K16 via forming hydrogen bonds and this interaction could alter/edit the surface charge of Aβ, which could consequently interfere the binding between epitope and corresponding antibody (Fig. 1a) .
First, to validate that modification of surface charge of the Aβ peptide can alter antibody binding, e-amino of K16 was acetylated (Ac-K16-Aβ) to turn positive K16
into neutral, and the chemiluminescence readouts from native Aβ peptide and Ac-K16-Aβ were compared using 6E10 antibody, which is reactive to 1-16 amino acids (a.a.).
Indeed, much lower intensity was observed from Ac-K16-Aβ group than that from the non-modified Aβ group (Fig.1b,c) , indicating the positive charge on K16 is critical for the binding between Aβ and 6E10 antibody. Next, 12-crown-4 was used to investigate whether it could have similar effects on the binding as the acetylation of K16. After mixing 12-crown-4 with peptides (native Aβ and Ac-K16 Aβ), we found that the intensity of native Aβ was significantly decreased, while no obvious signal change of Ac-K16 Aβ was observed (Fig.1d ,e and Supplementary Fig.1a ), suggesting that 12-crown-4 was capable of altering the charge status of the epitope. The altering of surface charge of Aβ by 12-crown-4 was further validated by zeta potential assays, which have been regularly used to measure changes of surface charge status. 15 As expected, the zeta potential of Aβ significantly increased after interacting with 12-crown-4, further confirming the charge/electrostatic editing within the epitopes (Fig.1f) .
Based on the encouraging results from the 12-crown-4 study, we set out to test its analogues Icotinib and 18-crown-6. 18-crown-6 showed similar editing effect on 7 binding as 12-crown-4 while Icotinib showed no significant editing effect (Fig.1g,h and Supplementary Fig.1b ). This may be due to the structure of Icotinib, which is relatively bulky to interact with the core of Aβs. Interestingly, 12-crown-4 and 18-crown-6 could only reduce the readout of aggregated Aβs but not monomeric and oligomeric Aβs ( Supplementary Fig.1c ). This is likely due to the positive charges buried inside the Aβ monomers and oligomers, which have less ordered transient states. 16 Next, we used Orange G as an additional example for editing K16, as previous X-ray analysis of atomic structure indicated the negatively charged sulfonic acid groups of Orange G could interact with positively charged K16. 9 As expected, Orange G showed similar results as crown ethers (Fig.1g,h ). Collectively, our results indicated that the positive charge on K16 was essential for the antibody binding and it could be altered/edited by crown ethers and Orange G. Hydrophobicity Editing of Aβs. It is estimated that paratopes, the antigen-binding site on antibodies, are enriched with aromatic residues (Tyr, Trp, and Phe), especially those with short hydrophilic side chains (Ser, Thr, Asp, and Asn). 6 Previously we reported that curcumin analogue CRANAD-17 could bind to Aβ species and attenuate crosslinking of Aβs, and 1 H NMR spectra showed that CRANAD-17 could interact with Aβ16-20 fragment, which is the core fragment of Aβ peptides. 17 The curcumin scaffold of CRANAD-17 serves as the anchor moiety for targeting the hydrophobic core of Aβ, 9 and we hypothesized that the benzene and imidazole rings on both sides of CRANAD-17 could altered/edited hydrophobic properties around Aβ17-24 epitope, which can be recognized by 4G8 antibody (Fig. 2a) . To this end, the chemiluminescence readouts from Aβs with or without CRANAD-17 were compared using 4G8 antibody. Thioflavin T (ThT), a standard dye for Aβ plaques but not specific to Aβ17-24, 18, 19 was used as a negative control. We found that CRANAD-17 group displayed significantly enhanced chemiluminescence intensities for all Aβ species (Fig.2b ,c and Supplementary Fig.2 for oligomers and aggregates). Although we expected CRANAD-17 to change the readouts, the increase in chemiluminescence intensity was surprising. For ThT, our data showed no apparent changes of Aβ species with and without ThT, which is in accordance with previous study that ThT primarily binds in channels running parallel to the long axis of Aβ fibrils ( Supplementary Fig.3 ). 18 To investigate the specificity and sensitivity of this method, we used Aβ 6E10 antibody (reactive to Aβ1-16) for comparison. As shown in Table 1) . Taken together, CRANAD-17 could alter/edit the hydrophobicity of Aβ17-24 epitope to facilitate antibody binding.
The above results of CRANAD-17 were obtained from pure solution tests.
However, it was not clear whether CRANAD-17 has similar editing effect on Aβs in a biologically relevant environment. In this regard, we used the media from 7PA2 cells, which is a familial APP mutation transfected cell line that secretes Aβ1-40 and Aβ1-42.
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Despite the low concentration of Aβ in cell media, the epitope editing effect could still be detected ( Supplementary Fig. 7a,b ). In addition, transgenic mice brain homogenate displayed enhanced readout after interacting with CRANAD-17 ( Supplementary Fig.   7c ,d). These data suggests that CRANAD-17 could execute its editing effect in biologically relevant environment.
Over the past several years, we have synthesized numerous curcumin analogues CRANAD-Xs. 24 To investigate whether these analogues have similar a effect as CRANAD-17, we used the SPEED to test CRANAD-Xs (X= -3, -25, -44 and -102)
( Supplementary Fig.8,9 ). We found that these compounds could alter the 4G8 antibody recognition and lead to increased chemilumiescence intensity. Interestingly, we found that CRANAD-102 was not able to edit the epitope from insoluble Aβ aggregates Functional Studies for Epitope Editing. The charges on e-amino of lysines of Aβ, which are capable of forming salt bridges to stabilize mis-folded conformations, play an important role in Aβ aggregation and neurotoxicity. 9 Previously, we found that 12-13 crown-4 showed decreased level of Aβ aggregates, confirmed by fluorescence assay and TEM observation. 13 To further prove that the charge editing effect could break the salt bridge of Aβ and change protein aggregation behaviors, SDS-page gel studies were performed. As expected, the addition of 12-crown-4, 18-crown-6 and Orange G significantly changed aggregation behaviors of Aβs, as indicated by reduced aggregation of low molecular weight of Aβs ( Supplementary Fig.10 ).
Previous studies indicated that Aβ species could initiate antibody production in vivo. 7, 25 Importantly, microglia activation depends on Aβ conformation and core fragment/epitope of Aβ is related to neuroinflammation. 26 We speculated that editing the hydrophobicity of epitope Aβ17-24 with CRANAD-17 could change immuneresponses of Aβ and consequently alter pro-inflammatory properties of Aβ.
To this end, we determined the cytokine secretion of human microglia cells mice, which were treated with CRANAD-17 for 3 weeks at the age of 9-month old, and sacrificed at the end of treatment. The brain slides were co-stained with anti-Aβ antibody 3D6 (for Aβ plaques) and microglia specific antibody IBA-1 (for microglia activation). We quantified the relative microglial activation using the intensity ratio of IBA-1 and 3D6 staining of the same plaques, and we found that CRANAD-17 treatment showed significantly decreased microglial activation (Fig.4a,b) . In addition, we also found that the plaques were smaller after the treatment (Fig.4c) . Taken together, our results suggested that epitope editing could lead to functional changes of target protein in vitro and in vivo. 
Discovery of Obatoclax as a Lead Imaging Ligand for Aβs via a Small Library
Screening. To explore whether SPEED can be used to discover new leads for drug discovery and seeking imaging ligands for Aβs, we performed screening with a small library of 32 compounds that are FDA approved drugs or drug candidates. The full list of the compounds are shown in Supplemental Table 2 and Table 3 . Indeed, the screening results showed that obatoclax, an inhibitor of Bcl-2 protein, 27 and GNF-5837, a tropomyosin receptor kinase (Trk) inhibitor, 28 showed significantly increased signal for Aβs with 4G8 antibody (Fig.5a,b) . To confirm whether the obatoclax hit is true positive hit, we performed a concentration-dependent titration. As expected, obatoclax showed an excellent dose-dependence for Aβ binding (Fig.5c,d ). To further validate that obatoclax is able to bind to the epitope of Aβ17-24, we performed molecular docking studies. The results confirmed that the interacting sites of obatoclax contain Aβ17-24.
( Fig.5e, Supplementary Fig.6 and Supplementary Table 1) .
Given the fluorescent properties of obatoclax, we then validated whether obatoclax could be used as a fluorescent imaging probe for Aβ species, we performed ex vivo histological observation of 5xFAD and wild-type mice brain. After intravenous injection of obatoclax, the mice brains were sliced and observed with fluorescence microscopy. The sections of 5xFAD mouse brain showed substantial staining of Aβ plaques that were further confirmed by subsequent ThS staining, while wild-type mouse brain showed no labeling (Fig.5f ). These results indicated that obatoclax could potentially be used for fluorescence imaging Aβ plaques and the SPEED platform could be applied for seeking imaging probes.
We also noticed that GNF-5837 was orange and could be a potential fluorescent probe for Aβs. However, we found that it was not able to provide acceptable contrast for Aβ plaques in an AD mouse brain slice, which is likely due to the low quantum yield of GNF-5837. Therefore, no further action was taken for this compound. . These data suggests obatoclax could potentially be used for fluorescence imaging of Aβs and the SPEED platform could be applied for seeking imaging probes.
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Application of SPEED for Other Targets. To further validate the applicability of the SPEED strategy, other targets were tested. Tau protein, which is a microtubuleassociated protein with a critical role in several tauopathies include AD, Parkinson's disease and Pick's disease, was selected as a target protein. [29] [30] [31] The VQIVYK segment of tau protein has been shown to drive tau aggregation and thus is considered an important target for seeking inhibitors for inhibiting tau fibrilization. However, the clear interaction mechanism between tau fibrils and inhibitor is still elusive. To test whether several commercially available tau inhibitors, tracers and dyes can alter the epitope VQIVYK segment, we selected ATPZ, T-807 and thioflavin S (ThS) to conduct the assay. [29] [30] [31] As shown in Fig.6a ,c, ThS showed significantly increased signal upon interacting with tau protein, which is in accordance with previous studies that indicate ThS could bind to the VQIVYK fragment. 31 In constrast, the editing effect of ATPZ and T-807 on VQIVYK-contained epitope is negligible (Fig.6a-d include small molecule BMS-202 and peptide WL12 were selected for the testing. 32, 33 As shown in Fig.6e -h, the readout of WL12 significantly decreased while BMS-202 displayed no obvious change compared to the blank control. This may arise from the flat and large interface of antibody-antigen interaction that makes it even more difficult for small molecular inhibitors to compete the binding. 34 Several concentrations of WL12 were then used for the assay, further confirming the editing effect of epitope (Fig.6f,h ). Taken together, our platform could be used to screen ligands for various targets and different classes of drug candidates, including both small molecules and peptide drugs. 
Discussion
Currently, only a few methods enable direct and label-free screening, 35 ,36 including drug affinity responsive target stability (DARTS), 37, 38 and surface plasmon resonance (SPR) technology. 39 In this report, we demonstrated that, as proof-of-concept, epitope editing could be used to seek ligands for a target of interest, which requires no modification/tagging and no extra equipment. In our exploratory investigation, several examples were successfully demonstrated, including Aβ peptides, tau and PD-L1
proteins. The molecular weights of these targets of interest span from 4KD to 55KD, which represents a wide range of proteinoid targets. We showed that this platform was not only suitable for targets related to Alzheimer's disease, but also for cancer immunology-related protein PD-L1. Although our examples are related to proteinoids, we believe that our platform can be expanded into other non-proteinoid of targets, such as oligosaccharides, a very common category of antigens for immune reactions.
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In the course of our studies, we discovered that CRANAD-Xs, obatoclax, GNF-5837 (Aβ) could enhance the readout signals. We speculated two possible reasons for this interesting phemonema: 1) as paratopes favor binding to aromatic rings from epitope via hydrophobic interactions, 6 it was reasonable to speculate that these compounds could provide several aromatic rings within the epitope and thus enhance the binding to antibody, which is in accordance with recent discovery of protein-protein interaction (PPI) stabilizers that showed cooperative roles in PPI; 40, 41 2) our data suggests CRANAD-17 could change the hydrophobicity of epitope and it is possible that the binding may cause conformational change of the epitope and "open up" the epitope, which could be recognised by antibody as enhanced signal. Despite the elusive mechanism, the readout changes indeed indicate the altering/editing of epitope that could be used for drug screening.
Notably, this phenomenon also provided several important implications: 1) the binding of antigen to antibody could be enhanced via epitope editing, and the therapeutic effects of the antibody could be potentially boosted; 2) although CRANAD-X and Aβ antibody bind to the same epitope region, they are not in a competitive relationship, which differs from other drug screening methods based on inhibiting titration; and 3) cautious interpretation might be necessary for results from ELISA and dot blot if compound treatment was applied in the studies. protein interface, and hence the hot spot is potentially important for drug discovery. 34 Our platform could designate a specific site/epitope for screening related hits, thus could provide rationale-based screening to potentially decrease the laborious screening supplemented with 2 mM L-glutamine, 200 μg/ml G418, 100 IU/mL penicillin, and 100 μg/mL streptomycin at 37 °C in an atmosphere containing 5% CO2. . After 1 h incubation at room temperature, the mixture was subjected to routine SPEED test with LVFFAEDV as EOI (n = 2 in each assay, assay performed at least in duplicate, more information in Supplementary Table 2 and Table 3 ). The P values between control and tested group were determined by two-tailed Student's t-test and the compounds with P < 0.0001 were selected as the hits.
Ex Vivo Histological Staining. 9-month old 5xFAD mice and wild-type mice were intravenously injected with 100 uL obatoclax solution (1mg/ml, 5% DMSO, 5% cremorpho1, 90% PBS) via tail vein and sacrificed at 60 minutes post-injection. The 30 brains were harvested and cut into 10 μm slices and then co-stained with 0.1% Thioflavin S (50% ethanol). After washing the slices with 80% ethanol for 1min, 70%
ethanol for 1min and distilled water for 2 × 1 min, the fluorescence images were captured by using a Nikon Eclipse 50i microscope.
Statistical analyses.
Quantitative data shown as mean ± s.e.m. were analyzed and presented with GraphPad Prism 8.0 software. P values were determined by unpaired two-tailed Student's t-tests to evaluate the difference between two groups. The differences were considered significant when P ≤ 0.05.
